



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 23-D-044**

We responded to your Freedom of Information request 23-C-012 on 24<sup>th</sup> April 2023. In relation to our response to Freedom of Information request ref 23-C-012, you asked:

### **1. Were all General Practitioners having such patients also alerted?**

The change, which is in line with recommendations in NICE guidelines (from 2018) and accepted practice nationally which is reflected in a local prescribing guidelines, was agreed via:

- Mental Health & Learning Disabilities Drugs & Therapeutics Committee
- Primary Care Prescribing Advisory Group
- SBU Medicines Management Operational Board

All these groups have GP and Local Medical Committee (LMC) representation. In addition, all GP practices were notified by the Primary Care Medicines Management technicians when the patient's prescriptions were being transferred and an agreement was obtained from each.

Prescribing via the GP brings SBUHB in line with nationally accepted practice.

### **2. Were GP's advised of these changes before they were implemented and thus be in a position to monitor any non requests from their patients? My Practice were unaware of any coming change and had not stepped in to take on the prescribing responsibility.**

Yes – please see question 1.

### **3. Would you know the scale of any diminution in the prescribing of such tablets?**

There has been no diminution in the prescribing of these medications since the implementation of the changes.



